The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial
Peter Dubsky(Hirslanden Klinik St. Anna), Martin Filipits(University of Vienna), Ralf Kronenwett(Beth Israel Deaconess Medical Center), Stephanie Meek(Myriad Genetics), Angelika Pichler, Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Richard Greil(Paracelsus Medical University), Daniel Egle(Innsbruck Medical University), Margaretha Rudas(Comprehensive Cancer Center Vienna), Marija Balić(University of Pittsburgh), Edgar Petru(Medical University of Graz), Christian F. Singer(Comprehensive Cancer Center Vienna), Viktor Wette, Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna)
Cited by 52
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k